Be the first person to write a business review for Lifecore Biomedical, Inc.

LifeSpan BioSciences likes the way genes express themselves. The firm helps drugmakers develop new product candidates faster by finding proteins and RNA in human tissue samples to identify gene expression associated with disease. It licenses access to its databases of gene expressions and protein localizations to drug developers. Also available are target validation and tissue pathology services. LifeSpan's clients include pharmaceutical companies in Asia, Europe, and North America.

Ligand Pharmaceuticals Incorporated company was founded in 1987. Ligand Pharmaceuticals Incorporated (Ligand) is a biotechnology company that focuses on drug discovery and early-stage development of pharmaceuticals that address critical unmet medical needs or that are more effective and/or safer than existing therapies, more convenient to administer and are cost effective. The Company has research and development collaborations for its product candidates with numerous pharmaceutical companies. These collaborations include ongoing clinical programs at Bristol-Myers Squibb (BMS), GlaxoSmithKline (GSK), Pfizer, Schering-Plough, Wyeth, Cephalon and Celgene. It receives royalty revenues from King Pharmaceuticals (King), and GSK. In February 2007, it completed the sale of its AVINZA product line to King. Through October 2008, it received a 15% royalty on AVINZA net sales. On December 23, 2008, it acquired all of the outstanding common shares of Pharmacopeia, Inc. In December 2009, Ligand Pharmaceuticals Incorporated acquired Neurogen Corporation.

Locus Pharmaceuticals' mission is discovering and developing drug treatments using a technology platform that integrates virtual drug design, medicinal chemistry, and biology. Through its Ansaris division the company researches small molecule treatments for a number of illnesses including HIV, cancer, and inflammatory conditions such as arthritis. The company aims to develop drug candidates in-house and partner with other drugmakers to co-develop drugs. Locus counts Novartis Institute of Biomedical Research and Ono Pharmaceuticals among its partners. The privately-held company is led by president Joan Lau. Investors include Norvartis Bioventures and founding investor, Prism Venture Partners.

Lonza Biologics plc, one of The Lonza Group's four biologic contracting manufacturing sites, is a leading contract manufacturer of monoclonal antibodies, recombinant proteins, and diagnostic monoclonal antibodies that are used to produce pharmaceuticals. Lonza Biologics conducts research and development on mammalian cell culturing involving cloning from non-animal origins. From its manufacturing facility near London, the company also supplies its products to other biotechnology companies.

Lorus Therapeutics isn't talking nonsense, they're talking antisense. The biotechnology firm is developing cancer drugs using antisense technology, which prevents cells from producing disease-causing proteins and may cause fewer side effects than traditional chemotherapies. It is testing its lead candidate in this area, LOR-2040, as a treatment for various blood cancers and solid tumors. Lorus is working in other areas of cancer research as well, developing some traditional therapies, as well as immunotherapies, which stimulate the body's immune system to fight cancer. The company licensed its Virulizin immunotherapy, a potential treatment for pancreatic cancer, to a subsidiary of Zoticon Bioventures in 2008.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.